We are live on
!
Find out more
PC
Polar Capital Portfolio holdings
AUM
$13.5B
1-Year Est. Return
55.9%
This Fund
S&P 500
This Quarter
Est. Return
+15.78%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$13.5B
AUM Growth
+$1.89B
(+16%)
Cap. Flow
+$530M
Cap. Flow
% of AUM
3.93%
Top 10 Holdings %
Top 10 Hldgs %
31.71%
Holding
339
New
59
Increased
111
Reduced
94
Closed
41
Top Buys
| 1 |
Meta Platforms (Facebook)
META
|
+$157M |
| 2 |
Johnson & Johnson
JNJ
|
+$155M |
| 3 |
Chegg
CHGG
|
+$87.6M |
| 4 |
Medtronic
MDT
|
+$72.1M |
| 5 |
Humana
HUM
|
+$69.3M |
Top Sells
| 1 |
UnitedHealth
UNH
|
+$133M |
| 2 |
Ciena
CIEN
|
+$99.1M |
| 3 |
Advanced Micro Devices
AMD
|
+$79.2M |
| 4 |
IMMU
Immunomedics Inc
IMMU
|
+$73.2M |
| 5 |
AYX
Alteryx Inc
AYX
|
+$70M |
Sector Composition
| 1 | Technology | 35.47% |
| 2 | Healthcare | 19.83% |
| 3 | Financials | 14.52% |
| 4 | Communication Services | 13.91% |
| 5 | Consumer Discretionary | 8.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Bruker
BRKR
$8.86B
| $224K | ﹤0.01% |
+5,632
| New | +$235K |
|
277
CALL
Alibaba
BABA
$276B
| $206K | ﹤0.01% |
+700
| New | +$184K |
|
278
Vericel Corp
VCEL
$2.38B
| $206K | ﹤0.01% |
+11,108
| New | +$184K |
|
|
GNMK
279
DELISTED
GenMark Diagnostics, Inc
GNMK
| $158K | ﹤0.01% |
+11,100
| New | +$170K |
|
280
Agios Pharmaceuticals
AGIO
$2.36B
| – | – |
-150,000
| Closed | -$8.02M |
|
281
Angi Inc
ANGI
$248M
| – | – |
-46,249
| Closed | -$5.62M |
|
282
Assembly Biosciences
ASMB
$531M
| – | – |
-1,041
| Closed | -$291K |
|
|
BAND
283
Bandwidth Inc
BAND
$2.3B
| – | – |
-66,087
| Closed | -$8.39M |
|
|
284
Ciena
CIEN
$53B
| – | – |
-1,829,458
| Closed | -$99.1M |
|
285
Crinetics Pharmaceuticals
CRNX
$8.88B
| – | – |
-175,000
| Closed | -$3.07M |
|
286
Cytokinetics
CYTK
$10.9B
| – | – |
-500,000
| Closed | -$11.8M |
|
287
Quest Diagnostics
DGX
$23.3B
| – | – |
-464,029
| Closed | -$52.9M |
|
288
DaVita
DVA
$15.2B
| – | – |
-570,000
| Closed | -$45.1M |
|
289
8x8 Inc
EGHT
$267M
| – | – |
-194,395
| Closed | -$3.11M |
|
290
Gilead Sciences
GILD
$167B
| – | – |
-225,000
| Closed | -$17.3M |
|
|
HOLX
291
DELISTED
Hologic
HOLX
| – | – |
-1,041,537
| Closed | -$59.4M |
|
292
Hexcel
HXL
$7.83B
| – | – |
-149,472
| Closed | -$6.76M |
|
293
Intel
INTC
$478B
| – | – |
-1,006,608
| Closed | -$60.2M |
|
294
Lumentum
LITE
$57B
| – | – |
-511,363
| Closed | -$41.6M |
|
295
MongoDB
MDB
$25.1B
| – | – |
-79,240
| Closed | -$17.9M |
|
296
Merck
MRK
$315B
| – | – |
-282,722
| Closed | -$20.9M |
|
297
Okta
OKTA
$26B
| – | – |
-213,370
| Closed | -$42.7M |
|
298
Penumbra
PEN
$12.5B
| – | – |
-1,569
| Closed | -$281K |
|
299
Impinj
PI
$4.21B
| – | – |
-189,072
| Closed | -$5.19M |
|
300
Replimune Group
REPL
$859M
| – | – |
-375,000
| Closed | -$9.32M |
|
Similar funds
ECM
FAAS
WAM
FS
NIMC
TI
VIM
PS
Polar Capital's Q3 2020 Portfolio in Review
As of Q3 2020, Polar Capital held 339 positions worth $13.5B, up 16% from $11.6B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Polar Capital deployed $530M of net new capital in Q3 2020, opening 59 new positions and adding to 111 existing holdings. Its largest new stake was Chegg: 1,189,909 shares worth $85M.
By sector, the portfolio is most concentrated in Technology at 35% of assets, down from 36% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was UnitedHealth, an estimated $133M trimmed.
- Polar Capital's largest Q3 2020 buy was Chegg: 1,189,909 shares worth $85M.
- Polar Capital added most to Meta Platforms (Facebook) in Q3 2020, an estimated $157M increase.
- Polar Capital's biggest Q3 2020 reduction was UnitedHealth, cutting an estimated $133M.
- Polar Capital fully exited Ciena in Q3 2020, selling an estimated $99.1M.
- Polar Capital's ten largest holdings make up 32% of its $13.5B portfolio in Q3 2020.
- Polar Capital opened 59 new positions and closed 41 in Q3 2020.
- Polar Capital's portfolio value rose 16% quarter-over-quarter to $13.5B.
Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.